Efficacy and safety evaluation of Vamorolon in the treatment of Duchenne muscular dystrophy (DMD) in the real world

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400091210

Enrollment

Unknown

Registered

2024-10-23

Start date

2024-10-23

Completion date

Unknown

Last updated

2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne muscular dystrophy

Interventions

Experimental group:Vamorolon

Eligibility

Sex/Gender

Male

Age

4 Years to 18 Years

Inclusion criteria

Inclusion criteria: (1) Male children with DMD who first used Vamorolon at age 4 or older; (2) Sign informed consent (3) Follow the research procedures and cooperate to complete the whole research process (4) The legal guardian of the child promises to abide by the research procedures and cooperate with the implementation of the whole process of the study

Exclusion criteria

Exclusion criteria: (1) The patient had used Vamorolon before the study (2) Exclude muscle weakness caused by other congenital or acquired diseases; (3) Exclude infectious diseases such as tuberculosis and hepatitis B; (4) Exclude neoplastic diseases; (5) Rule out autoimmune diseases;

Design outcomes

Primary

Measure	Time frame
NSAA;6min walking test;TTClimb;	—

Countries

China

Contacts

Public ContactYuan Xiao

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

xy11438@rjh.com.cn+86 186 2107 8359

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026